RNVA — Rennova Health Income Statement
0.000.00%
Last trade - 00:00
- $4.31m
- $16.01m
- $13.04m
- 72
- 99
- 48
- 85
2018 December 31st | R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 14.5 | 16 | 7.2 | 3.22 | 13 |
Cost of Revenue | |||||
Gross Profit | 3.04 | 1.24 | -4.58 | -2.07 | 6.27 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 20.2 | 31.5 | 21.7 | 10.5 | 14.2 |
Operating Profit | -5.66 | -15.4 | -14.5 | -7.28 | -1.2 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -12.8 | -46.6 | -19 | -5.09 | -2.96 |
Provision for Income Taxes | |||||
Net Income After Taxes | -13.6 | -46.6 | -17.6 | -5.27 | -3.27 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -14 | -48 | -18.3 | 5.61 | -3.29 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -246 | -172 | -282 | -501 | -334 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -248,968,993 | -305,588 | -94,569 | -9,339,238 | -0.033 |